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Abstract
Translation is a key step in protein synthesis in which the codons in messenger RNA (mRNA)
are decoded by the corresponding anticodon in transfer RNA (tRNA). Prior to translation, tRNAs
are modified by epitranscriptomic writers in order to ensure accurate decoding. During the
previous semesters, different strains of Escherichia coli (E. coli) were used where genes
corresponding to a tRNA modification enzyme were deleted from the genome. These strains
were from the Keio E. coli gene deletion library and included the epitranscriptomic writers:
CmoA, CmoB, Tgt, MnmE, QueA, ThiL, MnmC and TtcA. These strains were used to test the role
of tRNA modifications in protein synthesis during the stress response to the antibiotic
chloramphenicol (CAM). E.coli cells lacking the tRNA modification writers: selU, cmoA, cmoB,
tgt, queA, thiL, mnmC ttcA and mnmE showed CAM sensitivity. The database Modomics was
also used to identify RNA modifications and epitranscriptomic writers specific to the anticodon
loops of tRNA from E. coli and humans. Then BLAST analysis was used to identify human
homologs. Lastly, 27 human writers were analyzed for their links to cancer using The Cancer
Genome Atlas and cBioportal database. Various cancers were identified that have amplifications
in 5 of more writers and could be predicted to have changes in their epitranscriptome and may be
addicted to these RNA modifications to promote translation. The human epitranscriptomic
modifications: ALRYEF, CDKAL1, FTSJ1, GTPBP3, METTL11B, METTL18, METTL23 and
METTL24 were found to have high levels of alteration frequencies for specific cancer types,
with Bladder/ Urinary Tract cancer and Uterine Serous Carcinoma/ Uterine Papillary Serous
Carcinoma cancers the most pronounced.
Keywords: Escherichia coli, RNA modifications, Epitranscriptomic writers, Cancer,
Chloramphenicol
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Introduction
Transcription occurs when DNA is accessed and converted into mRNA. For actively
decoded mRNA species, translation can next occur in which the codons in mRNA are decoded by
the corresponding anticodon in tRNA to make a protein. In this process, mRNA and the fMettRNA, the initiator tRNA that brings in the first amino acid in proteins: methionine, binds to the
small subunit of ribosomal RNA (rRNA) with proper codon-anticodon pairing. The large
ribosomal subunit rRNA with three binding sites: A, P and E sites, joins the complex and the fMettRNA sits on the P site. The tRNA specific for a codon in the A site enters the ribosome. A peptide
bond is formed between fMet-tRNA of P site and the amino acid of A site. As ribosomes move in
a 5’ to 3’ direction on the mRNA, the peptidyl-tRNA relocates to the P site. A new codon is
exposed in the A site once again. This process continues until the ribosome reaches a termination
codon, which causes the peptidyl transferase to cleave the completed polypeptide chain from the
last tRNA (Griffiths et al., 2015).
During the pairing of the codon to the anticodon, the third position of codons has relaxed
pairing rules compared to the first two codon bases, due to a phenomenon known as wobble codonanticodon pairing (Griffiths et al., 2015). This breaks the Watson-Crick rules of base pairing as the
third base of the anticodon is capable of base pairing with more than one type of base (Griffiths et
al., 2015). In general, the anticodon base guanine (G) can interact with uridine (U) or cytosine (C)
in the codon; the C anticodon base can interact with G in the codon; an adenine (A) anticodon base
interacts with U in the codon; U anticodon base can interact with A or G in the codon; lastly, the
anticodon base inosine (I) can interact with A, U or C in the codon. This is important since 64
different tRNAs are not available in most cells to translate the different mRNA codons (Griffiths
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et al., 2015). Meanwhile, Inosine (I), a modified base found in tRNA, is one of many that is written
into tRNA by enzyme writer systems (Griffiths et al., 2015).
Prior to translation, tRNAs are modified by epitranscriptome writers in order to ensure
proper decoding. Below, I describe the enzymes I examine. The figures show where the chemical
moiety is deposited and the extent to which the nucleotide within the tRNA is modified.
The tRNA modification enzymes: 5-carboxymethoxyuridine methyltransferase (CmoM),
5-methylaminoamethyl-2-thiouridine (MnmC), 5-carboxymethyl aminomethyl uridine (MnmE),
carboxymethyltransferase (CmoB), and carboxy-S-adenosyl-L-methionine synthase (CmoA) are
involved in wobble uridine modification (U34) in the bacteria E. coli (Keseler et al., 2017). The
U34 wobble base of tRNAs (Ala, Ser, Pro and Thr) is modified by the enzyme CmoM, as it
catalyzes the final step of 5-methoxycarbonylmethoxyuridine (mcmo5U) modification through the
transfer of a methyl group from S-adenosyl-L-methionine (SAM) to 5-methoxycarbonyl methyl
uridine (mcm5U) (Kim et al., 2013).

Figure 1
Chemistry of the CmoM Modification in tRNAs. (The UniProt Consortium, 2021)
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Figure 2
CmoM Modifies tRNAs Ala and Ser at the U34 position (circled in red)
Note. The black dots and semi circles represent all of the areas where tRNAs modifications occurs
as well as the frequency. The extent of the filled in circle represents how often the nucleotide is
modified at the respective position (Boccaletto et al., 2017).
CmoA and CmoB are required for the formation of 5-oxyacetyl uridine (cmo5U)
modification through the transfer of carboxymethyl group (Keseler et al., 2017). CmoA specifically
catalyzes the conversion of SAM to carboxy-S-adenosyl-L-methionine (Cx-SAM), to facilitate the
formation of a modified base at the U34 wobble position (Kim et al., 2013).

Figure 3
Chemistry of CmoA modification of SAM (The UniProt Consortium, 2021).
3

Meanwhile, CmoB catalyzes the transfer of the carboxymethyl group from carboxy-Sadenosyl-L-methionine (Cx-SAM) to 5-carboxymethoxyuridine (cmo5U) at U34 wobble base
(Figure 4) (Kim et al., 2013).

Figure 4
Chemistry of CmoB modification in tRNAs (The UniProt Consortium, 2021).

MnmC catalyzes the formation of 5-methylaminomethyl-2-thiouridine (mnm5s2U) from 5carboxymethylaminomethyl-2-thiouridine (cmnm5s2U) for tRNAs (Glu, Lys and Gly) (Figure 5)
(Keseler et al., 2017).

Figure 5: Chemistry of MnmC modification in tRNAs (The UniProt Consortium, 2021).
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MnmE adds a carboxymethylaminomethyl (cmnm) group at the wobble position (U34) for tRNAs
(Lys, Leu, Glu, Gln, Gly and Arg) and is necessary for the biosynthesis of 5-methylaminomethyl2-thiouridine (mnm5s2U) modification (Figure 6 and Figure 7) (Elseviers et al., 1984).

Figure 6
Chemistry of MnmE modification in tRNAs. (Boccaletto et al., 2017).

Figure 7
MnmE modifies the tRNAs Lys, Leu, Glut, Gln, Gly and Arg at the U34 position (circled in red).
Note: The black dots and semi circles represent all of the areas where tRNAs modifications occurs
as well as the frequency. The extent of the filled in circle represents how often the nucleotide is
modified at the respective position (Boccaletto et al., 2017).
5

Similarly, the enzymes: S-adenosylmethionine ribosyltransferase-isomerase (QueA) and
guanine transglysylase (Tgt) are involved in wobble G modification. Tgt catalyzes the posttranscriptional base exchange of guanine (G) with queuine precursor (PreQ1) in tRNAs (Asp, Asn,
His and Tyr) (Figure 8 & Figure 9) (Keseler et al., 2017; The UniProt Consortium, 2021).

Figure 8
Chemistry of Tgt modification in tRNAs (Boccaletto et al., 2017).

Figure 9
Tgt modifies the tRNAs Asp, Asn, His, and Tyr at the U34 position (circled in red).
Note. The black dots and semi circles represent all of the areas where tRNAs modifications occurs
as well as the frequency. The extent of the filled in circle represents how often the nucleotide is
modified at the respective position (Boccaletto et al., 2017).
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The formation of the anticodon loop modification in tRNA requires QueA for the addition of the
2,3-epoxy-4,5-dihydroxycyclopentane ring to epoxyqueuosine in tRNAs (Asp, Asn, His and Tyr), (Keseler
et al., 2017).

Figure 10
Chemistry of QueA modification in tRNAs (Boccaletto et al., 2017).

Figure 11
QueA modifies the tRNAs Asp, Asn, His, and Tyr at the U34 position (circled in red).
Note. The black dots and semi circles represent all of the areas where tRNAs modifications occurs
as well as the frequency. The extent of the filled in circle represents how often the nucleotide is
modified at the respective position (Boccaletto et al., 2017).
7

2-selenouridine synthase (SelU) catalyzes the conversion of 2-thiouridine (s2U-RNA) to 2selenouridine (Se2U-RNA) at the U34 wobble base of three different tRNAs (Lys, Glu, Gln)
(Figure 12 & Figure 13) (Keseler et al., 2017).

Figure 12
Chemistry of SelU modification in tRNAs (Boccaletto et al., 2017).

Figure 13
SelU modifies the tRNAs Lys, Glu and Gln at the U34 position (circled in red).
Note. The black dots and semi circles represent all of the areas where tRNAs modifications occurs
as well as the frequency. The extent of the filled in circle represents how often the nucleotide is
modified at the respective position (Boccaletto et al., 2017).
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Lastly, the enzymes thiamine monophosphate kinase (ThiL) and cytidine(32) 2sulfurtransferase (TtcA) are involved in thio-modification of tRNAs (Keseler et al., 2017). ThiL
catalyzes the phosphorylation of thiamine monophosphate to produce thiamine diphosphate
(Imamura et al., 1982; Nakayama et al., 1972).

Figure 14
Chemistry of ThiL modification in tRNAs (The UniProt Consortium, 2021).
TtcA catalyzes the ATP-dependent 2-thiolation of cytidine in position 32 of tRNA (Arg ad
Ser) to produce 2-thiocytidine (s2C32) (Bouvier et al., 2014).

Figure 15
Chemistry of TtcA modification in tRNAs (Boccaletto et al., 2017).
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Figure 16
TtcA modifies the tRNAs Arginine and Serine at the C32 position (circled in red).
Note. The black dots and semi circles represent all of the areas where tRNAs modifications occurs
as well as the frequency. The extent of the filled in circle represents how often the nucleotide is
modified at the respective position (Boccaletto et al., 2017).
Chloramphenicol (CAM) is a lipid soluble, broad spectrum antibiotic that reversibly binds
to the 50S subunit of ribosomes. It diffuses through the bacterial cell membrane and acts by
preventing the formation of peptide bonds by suppressing peptidyl transferase activity (Bartlett,
1982). Chloramphenicol was first derived from Streptomyces venezuelae in 1947 but is now
synthetically made (Bartlett, 1982). It can cause severe side effects such as damage to bone marrow
and aplastic anemia and thus is only used to treat serious bacterial infections such as cholera,
typhoid fever, meningitis caused by bacteria. It is also used in eye drops and ointments to treat
bacterial conjunctivitis. Chloramphenicol falls under the amphenicol class of antibiotics due to its
phenylpropanoid structure.
In my work, I used E. coli mutants (part of the Keio gene deletion library) deficient in
specific epitranscriptomic writer enzymes. The Keio gene deletion library is a collection of K-12
strains in the BW25113 background of E. coli, each being a mutant with a single gene deleted and
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replaced with a kanamycin resistance gene through homologous recombination (Baba et al., 2006).
These mutants can be used to assess and analyze the functions of different genes (Baba et al.,
2006). Results from my work showed that strains of E.coli cells lacking the tRNA modification
writers: SelU, CmoA, CmoB, Tgt, and MnmE had a disrupted stress response while a different Keio
strain lacking the tRNA modification writers: queA, thiL, mnmC. ttcA and mnmE also showed
sensitivity to CAM. After this, RNA from mutant

selU was isolated in order to identify RNA

modification levels using mass spectrometry analysis in the future.
In this work, I also analyzed RNA modification enzymes thorough computational analysis.
One database, Modomics: http://genesilico.pl/modomics/ (Boccaletto et al., 2017), can be used to
gather information about modifications, pathways, RNA sequences, proteins, guide RNAs and
building blocks of numerous different organisms including E. coli. Specifically, for tRNA
modification enzymes, information about writer protein sequences, enzymatic activities, position
of catalyzed modification, sequence identifier number (GI number), open reading frame (Orf),
cluster of orthologous groups for phylogenetic classification (COG), and summary of the activity
pathway can be found. Using information from Modomics, such as the GI number, Basic Local
Alignment Search Tool (BLAST) analysis can be performed. BLAST is a program as well as an
algorithm tool that can be used to find similarities between biological sequences (Altschul et al.,
1990). It forms local alignment for a given sequence by comparing/aligning to various sequence
databases (Altschul et al., 1990). There are different versions for aligning different sequences:
nucleotide to nucleotide, translated nucleotide to protein, translated protein to nucleotide and
protein to protein (Altschul et al., 1990). For this project, BLAST analysis was used to determine
if the writer enzyme is specific to just bacteria or just humans, or if the writer enzymes were
conserved between species. In general, almost all of the tRNA modification enzymes mentioned
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previously were found to be homologous in some disease-causing organisms such as
Mycobacterium tuberculosis, Vibrio cholera, Haemophilus influenza, Streptococcus pneumonia
and Salmonella enterica; however, homology was not found with human genes.
Lastly, human epitranscriptomic writer enzymes were analyzed for their roles in different
cancer types through cBioPortal database as a computational analysis tool. In general, cells
become cancerous through failures in multiple systems leading to uncontrollable cell division.
Specifically, different types of amplifications, deletions and mutations arise in genes that can
promote cell proliferation (Lodish et al., 2000). One type of mutation that may result in tumor
growth is through amplification (Lodish et al., 2000). For example, if there is a mutation that
leads to more than one copy of the same gene for positive cell division regulators, accumulation
of extra proteins can promote cancer (Lodish et al., 2000). Similarly, damage to or deletion of
negative cell regulator genes may lead to nonstop cell division, thus promoting tumor growth
(Lodish et al., 2000). As mentioned earlier, prior to translation, tRNAs are modified by
epitranscriptomic writers in order to ensure proper decoding and thus play an important role in
gene expression. Therefore, it can be hypothesized that mutations such as amplification and
deletions of epitranscriptomic writers could affect cancer development.
Thus, cBioPortal database was used to characterize mutations of human epitranscriptomic
enzymes on different cancer types. The cBioPortal database contains tools for investigating cancer
genomic data set from larger genomic databases like The Cancer Genome Atlas (TCGA) program
(Cerami et al., 2012; Gao et al., 2013). One of the many ways cBioPortal database can be used is
to analyze cancer types based on chromosomal amplification, mutation and deep deletion levels of
different epitranscriptomic writers (Cerami et al., 2012; Gao et al., 2013). For this project, 27
epitranscriptomic modification enzymes were analyzed for amplification, mutation and deep
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deletion levels. The epitranscriptomic modification enzymes of interest were: ALRYEF, ADAT3,
ALKBH1, ALKBH2, ALKBH3, ALKBH4, CDKAL1, CTU2, ELP2, ELP3, ELP4, ELP5, ELP6,
FTSJ1, GTPBP3, IKPKAB, METTL11B, METTL14, METTL15, METTL16, METTL17,
METTL18, METTL21A, METTL21C, METTL22, METTL23, and METTL24. Similar to the E.
coli cells that were sensitive when a specific writer was removed and could be used as a target for
antibiotics, epitranscriptomes with high levels of mutations for specific cancer types could be used
as potential target for cancer treatment. The human epitranscriptomic modification enzymes:
ALRYEF, CDKAL1, FTSJ1, GTPBP3, METTL11B, METTL18, METTL23 and METTL24 were
found to have high levels of alteration frequencies for specific cancer types.
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Materials and Methods

LB Liquid Media
To make 1000 mL of LB media (Becton, Dickson and Company, Sparks), 25.0 g of LB
powder was added into an autoclave bottle and the bottle was filled to 1000 mL with deionized
water. Stirring plate with a stirring rod inside the autoclave bottle was used to mix the powder
evenly with water. The cap of the autoclave bottle was put loosely on the bottle before placing the
bottle in the autoclave on liquid cycle.

LB Agar Media
To make agar plates, ~100 mL of distilled water was first added to a 1000 mL sterile
autoclave bottle. Then 12.5 g of LB media (Becton, Dickson and Company, Sparks) and 7.5 g of
agar (Becton, Dickson and Company, Sparks) was added to the bottle. The bottle was filled up to
500 mL with distilled water, a stir rod was added, and it was autoclaved for two hours. It was then
left to cool for another hour while stirring to prevent congealing. Afterwards, the media was poured
into the plates and left to cool until it was solid. Finally, the plates were put, upside down and
tilted, in the 55 °C incubator for 15 minutes to dry.

Sterile Streaking Technique
A loop was used to streak bacteria from a plate. First, the rod was sterilized using fire and
a single colony of bacteria was picked. The bacteria containing rod was then streaked into a new
plate by handling the rod at almost parallel level to the plate. The rod was sterilized before each
streaking. Then the streaked plates were placed in the 37 °C for 24 hours.
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RNA Isolation
The mutant strains were acquired from the Keio gene deletion library (Baba et al., 2006).
Each strain was streaked on kanamycin (5 µg/mL) agar plates. One colony of each strain was
inoculated for 18 hours in six separate, sterile tubes: three contained 10 mL LB broth with 3.4
µg/mL of CAM while three contained 10 mL of LB media. In order to ensure that good
concentration of bacteria had grown prior to RNA isolation, optical density of the inoculated media
was measured. These samples were then spun in a JA 25.5 rotor centrifuge for 20 minutes at 2,500
rpm and 20 °C. After discarding the supernatant without disturbing the pellet, 1 mL of TRIzol was
added to each sample to break apart the pellet. Chloroform (200 µL) was then added to each sample
which were then vortexed and incubated for 3 minutes. Samples were then centrifuged at 14,500
rpm for 15 minutes. 400 µL of the top layer of the sample was added to a new micro tube along
with 500 µL of isopropanol and rotated around 5 to 10 times and incubated for 10 minutes in room
temperature before centrifuging for 15 minutes at 14,500 rpm, 4 °C. Then the supernatant was
removed, and 1 mL of 70 % ethanol was added to the micro tube before centrifuging for 10 minutes
at 10,000 rpm, 4 °C. Finally, the ethanol was decanted, and the pellet was dried and solubilized
with deionized water. RNA concentration and purity were determined using NanoDrop 1000.

Computational Analysis: Modomics and BLAST
Using the protein button on the main page of Modomics: http://genesilico.pl/modomics/,
information about different tRNA modification proteins were found. After gathering information
on the protein, “Send to NCBI Blast” button on the top right of the summary page was pressed,
leading to the NCBI BLAST program that is already set with a GI number specific to the protein
of choice. There, several settings were changed: under organism, E. coli was excluded and under
“Algorithm Parameters”, the maximum targeted sequence was changed from 50 to 5000. The E15

value threshold was set to 0.05. Then BLAST was performed. Alignments for different organisms
along with the e-value under the “Organism” section of “Taxonomy” was tabulated.

Computational Analysis: cBioPortal Database
In the query tab on the main screen of cBioPortal database website:
https://www.cbioportal.org, “query the curated set of non-redundant studies” was selected. Under
the quick search tab, the gene of interest was selected. In the “Cancer Type Detailed” settings,
the minimum number of total cases was changed to 50 and the minimum percent of altered cases
was changed to 1%. The resulting graph along with the downloaded data from the top right
corner of the graph were used to analyze the different mutation levels. Lastly, the downloaded
data was compiled and clustered into heat maps using Morpheus:
https://software.broadinstitute.org/morpheus/.
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Results
Growth Inhibition of E. coli Using CAM
In order to investigate the roles of tRNA modification enzymes during stress response, 10
different E. coli mutants lacking a specific modification enzyme, along with wild type (WT), were
exposed to and grown in the presence (5 µg/mL CAM) or absence (0 µg/mL CAM) of
chloramphenicol antibiotic (CAM). As seen in Figure 17.1-19.1, all of the mutants and the wild
type cells grew on plates that did not contain CAM. Despite the 5-fold serial dilution that was
performed seven times, all of the mutants and wild type grew densely in the regular agar plate
lacking CAM. Some of the first strain of mutants showed growth defects in 5 µg/mL CAM plates
relative to the wild type (WT), and they included

queA,

thiL,

mnmC.

ttcA and

However, when the second strain of the mutants were grown on 5 µg/mL CAM, only
thiL,

mnmC.

ttcA and

mnmE showed sensitivity to CAM.
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mnmE.
queA,

Figure 17
Three of the mutants lacking cmoA, queA, cmoB, modifications along with the controls were
serially diluted, spotted on CAM agar plates and incubated overnight.

Figure 18
Three of the mutants, lacking tgt, selU, thiL, modifications along with the controls were serially
diluted, spotted on 0 and 5 ug/mL CAM agar plates and incubated overnight.

Figure 19
Four of the mutants, lacking cmoM, mnmC, mnmE, ttcA, modifications along with the controls
were serially diluted, spotted on 0 and 5 ug/mL CAM agar plates and incubated overnight.
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RNA Isolation and Purity
RNA concentration and purity were determined spectroscopically. Contamination of the
purified RNA with DNA, Trizol, ethanol, chloroform or isopropanol was also assessed using
NanoDrop 1000. The A260/280 ratio represents the level of DNA contamination, with 2 being
the ideal number. The A260/230 ratio represents the level of Trizol, ethanol, chloroform and
isopropanol contamination, with 2 being the ideal value. Lastly, ng/µL represents the concentration
of RNA in each sample. As seen in Table 1.1, compared to the rest of the samples, control 2
contained a lot of contamination. Similarly, CAM 1 sample had a lower concentration of RNA
compared to the rest of the samples.
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Table 1
Contamination of DNA (260/280), Trizol, ethanol, isopropanol and chloroform contamination
(260/230) and concentration of RNA (ng/µL) from RNA isolation of SelU mutants
260/280

260/230

ng/µL

Control 1

1.93

2.01

2938.5

Control 2

1.39

1.47

3821.2

Control 3

1.79

1.84

3349.2

CAM 1

1.99

2.02

2257.4

CAM 2

1.86

1.89

3258.1

CAM 3

1.84

1.84

3398.4

Homology of tRNA Modification Enzyme Genes
In order to analyze the homology of tRNA modification enzymes, Modomics and BLAST
programs were used. Genes are homologous to each other if they are conserved between different
organisms. As seen in Table 2.1, E. coli genes for the tRNA modification enzymes were found to
be homologous to corresponding proteins in organisms such as Mycobacterium tuberculosis,
Vibrio cholera, Haemophilus influenza, Streptococcus pneumonia and Salmonella enterica.
However, selU homologs were not identified in V. cholera. Similarly, no homologs were seen for
cmoA in H. influenzae and for mnmC in M. tuberculosis, V. cholerae, and H. influenzae. Yeast
mitochondrial ortholog known as Mss1 was also found for mnmE in Modomics but nothing was
found through BLAST alignment. Similarly, while a homolog for tgt was indicated for Homo
sapiens as TGT in Modomics, nothing was found through BLAST alignment. Menawhile, we can
see the Expect-value (E-value) of tRNA modification genes in different organisms in Table 3.1.
E-value indicates the statistical significance of the alignments. For each E-value, the number given
is the number of hits that is expected to be random and found by chance. As we can see from Table
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2.1, most of the E-value found is 0 or very close to 0. Hence, it can be concluded that these
alignments are non-random.

Table 2
Homology of tRNA Modification Genes
S. cerevisiae

cmoA

H.
sapiens
-

V. cholerae

-

M.
Tuberculosis
Homologous

S.
pneumoniae
Homologous

S. enterica

Homologous

H.
influenzae
-

cmoB

-

-

Homologous

Homologous

Homologous

Homologous

Homologous

mnmC

-

-

-

-

-

Homologous

Homologous

mnmE

-

Orthologous

Homologous

Homologous

Homologous

Homologous

Homologous

queA

-

-

Homologous

Homologous

Homologous

Homologous

Homologous

tgt

?

-

Homologous

Homologous

Homologous

Homologous

Homologous

selU

-

-

Homologous

-

Homologous

Homologous

Homologous

ttcA

-

-

Homologous

Homologous

Homologous

Homologous

Homologous

V.
cholerae
8.00E130
3.00E152
-

H.
influenzae
-

Homologous

Table 3
E-value of tRNA Modification Genes

cmoA

H.
sapiens
-

S.
cerevisiae
-

M.
tuberculosis
3.00E-137

S.
pneumoniae
3.00E-96

S. enterica

4.00E-156

0

0

-

0

0

1.00E-176

cmoB

-

-

1.00E-180

mnmC

-

-

-

mnmE

-

-

0

0

0

0

0

queA

-

-

0

0

0

0

0

tgt

-

-

0

0

0

0

0

selU

-

-

9.00E-154

-

0

0

0

ttcA

-

-

0

5.00E175

2.00E-171

0

0
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Computational Analysis of Human tRNA Modification Enzymes
In order to analyze human tRNA modification enzymes for theirs links to different cancer
types, cBioPortal database was used. Figures 20.1-46.1 shows the alteration frequency in
percentage (y-axis) of different cancer types (x-axis) for epitranscriptomic modifications obtained
from the cBioPortal database. In the graph, the different alteration types are given in different
colors: green represents mutations, red represents amplification, blue represents deep deletion,
purple represents fusion and grey represents multiple alterations. As seen in Figure 20.1, there was
13.88% amplification level in Bladder/ Urinary Tract for ALYREF modification. Amplification
level of 23.61% was seen in Bladder/ Urinary Tract cancer for CDKAL1 (Figure 26.1). Deep
deletion level of 24.09% was seen in Stomach Adenocarcinoma for FTSJ1 (Figure 33.1).
Amplification level of 14.68% was seen in Uterine Serous Carcinoma/ Uterine Papillary Serous
Carcinoma for GTPBP3 (Figure 34.1). For METTL11B, amplification levels of 25.31 %, 14.96%
and 13.95% were seen in Breast Mixed Ductal and Lobular Carcinoma, Breast Invasive Lobular
Carcinoma and Breast Invasive Ductal Carcinoma respectively (Figure 36.1). Similarly, for
METTL18, amplification levels of 25.73%, 15.2% and 14.05 % were seen in Breast Mixed Ductal
and Lobular Carcinoma, Breast Invasive Lobular Carcinoma and Breast Invasive Ductal
Carcinoma respectively (Figure 41.1). Amplification level of 13.89% were seen in Bladder/
Urinary Tract cancer for METTL23 (Figure 45.1). Lastly, mutation level of 13.46% was seen in
Prostate Neuroendocrine Carcinoma for METTL24 (Figure 46.1).
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Figure 20
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic reader ALYREF obtained from the cBioPortal database.

Figure 21
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ADAT3 obtained from the cBioPortal database.
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Figure 22
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ALKBH1 obtained from the cBioPortal database.

Figure 23
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ALKBH2 obtained from the cBioPortal database.
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Figure 24
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ALKBH3 obtained from the cBioPortal database.

Figure 25
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ALKBH4 obtained from the cBioPortal database.
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Figure 26
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer CDKAL1 obtained from the cBioPortal database.

Figure 27
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer CTU2 obtained from the cBioPortal database.
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Figure 28
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ELP2 obtained from the cBioPortal database.

Figure 29
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ELP3 obtained from the cBioPortal database.
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Figure 30
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ELP4 obtained from the cBioPortal database.

Figure 31
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ELP5 obtained from the cBioPortal database.
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Figure 32
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer ELP6 obtained from the cBioPortal database.

Figure 33
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer FTSJ1 obtained from the cBioPortal database.
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Figure 34
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer GTPBP3 obtained from the cBioPortal database.

Figure 35
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer IKPKAB obtained from the cBioPortal database.
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Figure 36
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL11B obtained from the cBioPortal database.

Figure 37
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL14 obtained from the cBioPortal database.
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Figure 38
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL15 obtained from the cBioPortal database.

Figure 39
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL16 obtained from the cBioPortal database.
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Figure 40
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL17 obtained from the cBioPortal database.

Figure 41
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL18 obtained from the cBioPortal database.
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Figure 42
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL21A obtained from the cBioPortal database.

Figure 43
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL21C obtained from the cBioPortal database.
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Figure 44
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL22 obtained from the cBioPortal database.

Figure 45
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL23 obtained from the cBioPortal database.
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Figure 46
Alternation frequency in percentage (y-axis) for different cancer types (x-axis) for the
epitranscriptomic writer METTL24 obtained from the cBioPortal database.

Several trends were seen when the different alteration types were clustered on a heat map
in which darker color corresponds to higher alteration frequency. As seen in Figure 47.1, the cancer
type that is most affected by amplification of the different epitranscriptome was found to be
Bladder/ Urinary Tract cancer. Although at very low frequencies for the most part, amplification
can also be seen in most of the modification enzymes in several cancer types: Serous Ovarian
Cancer, Uterine Serous Carcinoma, Prostate Adenocarcinoma, Adrenocortical Carcinoma, and
Dedifferentiated Liposarcoma. AlKBH4, CDKAL1, METTL11B and METTL18 were shown to
have the highest levels of amplifications compared to other epitranscriptomes. Similarly, Figure
48.1 shows Uterine Serous Carcinoma to be one of the cancer types most affected by deep deletion.
Compared to amplification levels, the lack of deep deletion of modification enzymes in different
cancer types is very noticeable. Lastly, as seen in Figure 49.1, cancer types with the highest levels
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of mutation frequency was found to be Uterine Endometrioid Carcinoma, Mucinous
Adenocarcinoma of the Colon and Rectum and Skin Cancer, Non-Melanoma. Similar to deep
deletion, many of the cancer types can be seen to lack in mutation of modification enzymes.

Figure 47
Compilation of amplification levels for 69 writers, erasers and readers in 65 different cancer types.
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Figure 48
Compilation of deep deletion levels for 69 writers, erasers and readers in 65 different cancer types.

Figure 49
Compilation of mutation levels for 69 writers, erasers and readers in 65 different cancer types.
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Discussion
Relative to the wild type, the mutants CmoA, CmoB, Tgt, and MnmE of the first strain and
the mutants QueA, ThiL, MnmC, TtcA, and MnmE of second strain were sensitive to CAM and
displayed perturbation. CmoA and CmoB are required for the formation of 5-oxyacetyl uridine
modification through the transfer of carboxymethyl group. Tgt is involved in the modified base
queuine in tRNAs Asp, Asn, His, and Tyr. MnmE is necessary for 5-methylaminomethyl-2thiouridine modification in tRNAs Lys, Leu, Glu, Gln, Gly and Arg. QueA is required for the
addition of the 2,3-epoxy-4,5-dihydroxycyclopentane ring to epoxyqueuosine in tRNAs (Asp,
Asn, His and Tyr) for the formation of the anticodon loop. ThiL catalyzes the phosphorylation of
thiamine monophosphate to produce thiamine diphosphate. MnmC catalyzes the formation of 5methylaminomethyl-2-thiouridine from 5-carboxymethylaminomethyl-2-thiouridine for tRNAs
(Glu, Lys and Gly). TtcA catalyzes the ATP-dependent 2-thiolation of cytidine in position 32 of
tRNA

(Arg

and

Ser)

to

produce

2-thiocytidine.

Meanwhile,

MnmE

adds

a

carboxymethylaminomethyl (cmnm) group at the wobble position U34 for tRNAs (Lys, Leu, Glu,
Gln, Gly and Arg) and is necessary for the biosynthesis of 5-methylaminomethyl-2-thiouridine
modification. Hence, we can speculate that these tRNA modifications and tRNAs play an
important role in inhibiting the effects of CAM in protein synthesis.
After the RNA isolation was completed and measured for 𝚫selU, compared to the rest of
the samples, we can see that control 2 contained a lot of DNA and other contaminations. Similarly,
CAM 1 sample had a lower concentration of RNA compared to the rest of the samples. Therefore,
our next step is to clean these samples to ensure that contamination does not interfere with future
experiments. In general, RNA samples isolated using TRIzol protocol can be cleaned with a spin
column kit such as RNA Clean and Concentrator kits (Norgen Biotek Corporation, 2016). In the
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future I would also purify RNA from other mutant cells, including 𝚫mnmC, 𝚫mnmE, 𝚫TrmO, Wild
type (as the positive control) and Alkb (as the negative control). Then, we will identify RNA
modification levels using mass spectrometry analysis in order to test if their absence alters RNA
modification levels and response to stress (CAM) (Basanta-Sanchez et al., 2006). Mass
Spectrometry is an analytical technique that can be used to identify proteins based on the mass to
charge ratio. The sample is digested with trypsin or other enzymes to make small peptides. Then
the mass to charge ratio is measured. This ratio is compared with a database to identify the proteins
(Brown et al., 2004).
Meanwhile, there are also other possible antibiotics that could be used for this experiment
due to their similarity to chloramphenicol. As mentioned earlier, amphenicol class antibiotics
includes antibiotics such as chloramphenicol thiamphenicol, florfenicol, etc., and works by binding
to the 50 S subunit. Similar to chloramphenicol, thiamphenicol works by inhibiting protein
synthesis but is more potent than chloramphenicol (Francis et al., n.d.). It is typically used as an
antibiotic for treating infectious diseases in cattle, poultry, pigs etc. (Francis et al.). While
thiamphenicol has similar side effects to that of chloramphenicol, it does not cause aplastic anemia
(Francis et al., n.d.). Florfenicol is another amphenicol class antibiotic that also inhibits protein
synthesis by binding to the ribosome (Florfenicol, 2007). It is also often used for veterinary
medicine and is not associated with aplastic anemia, unlike chloramphenicol (Florfenicol, 2007).
With these, we can compare and contrast the effects of CAM vs. other antibiotics in E. coli mutants
to speculate about what types of antibiotics affect which tRNA modifications enzymes found in E.
coli. Our next steps proceeding these results are also to replicate this experiment using the second
strains two more times, test them in different concentrations of CAM and attempt to rescue these
mutants back by adding back the deleted genes in E. coli.
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E. coli is useful in experiments due to its simplicity as compared to other organisms such
as yeasts and human cells. E. coli genome consists of around 4.6 million base pairs encoding
around 4,000 different proteins (Cells as Experimental Models). Meanwhile, Saccharomyces
cerevisiae (a type of yeast) has 12 million base pairs encoding around 6,000 genes and human
genome in general consists of about 3 billion base pairs, encoding around 100,000 different
proteins (Cells as Experimental Models). Similar to E. coli, yeasts and human cells have many
different stress response proteins and systems to manage different stressors. Research in S.
cerevisiae stress response include environmental stressors such as oxidative stress, metalloid and
metal stress, osmotic stress, heat shock etc. (Rodrigues-Pousasa et al., 2005). Much of the work
focuses on transcriptional regulation, particularly the Yap protein family that is involved in various
environmental stressors (Rodrigues-Pousasa et al., 2005). Similarly, many different types of stress
response proteins and thus systems exist for different types of cellular stress in human cells, such
as cytotoxic agents, heavy metals, genotoxic agents, calorie restriction, oxidative stress, and heat
(Nunes et al., 2019). These environmental stressors may trigger and/or contribute to different
diseases. Thus, stress responses such as tRNA methyltransferase Alkbh8 enzyme, required for
response against reactive oxygen species (ROS), are important for “restoring” the normal
physiology of cells (Endres et al., 2015; Nunes et al., 2019). The lack of these stress responses can
therefore lead to various diseases in humans. The tRNA methyltransferase Alkbh8 is homologous
in S. cerevisiae as tRNA methyltransferase 9 (Trm9) (Endres et al., 2015). Alkbh8 in humans and
Trm9 in S. cerevisiae catalyzes the methylation of 5-carboxymethyl uridine to 5methylcarboxymethyl uridine (Boccaletto et al., 2017). Similarly, mnmE, mentioned earlier as
important for the biosynthesis of 5-methylaminomethyl-2-thiouridine modification in E. coli, is
homologous in humans and S. cerevisiae as MSS1 (Gao et al., 2019).
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However, when mnmE was run through BLAST, no homology was observed in humans.
Similarly, while a homolog for tgt was seen for Homo sapiens as TGT in Modomics, nothing was
found through BLAST alignment. This could be because these genes are orthologous (when genes
diverge after speciation, but the main function is conserved) or paralogous (genes are duplicated
but the function and sequence composition may have changed) in humans (Haszprunar et al.,
1992). Therefore, a next step would be to use BLAST to compare different species with these genes
and compare which ones are most similar to each other in order to determine which types of
homology are found in humans. In order to determine the homology, studying the taxonomy for
these genes are also important. Meanwhile, E. coli genes for the tRNA modification enzymes were
found to be homologous to some disease-causing organisms such as Mycobacterium tuberculosis,
Vibrio cholera, Haemophilus influenza, Streptococcus pneumonia and Salmonella enterica. This
is important since the specific writer enzymes that are also found in these other bacteria can also
be explored as potential antibiotic targets. Similarly, amphenicol antibiotics may also be used as
potential antibiotics to treat illnesses caused by these bacteria.
Lastly, when investigating the roles of human epitranscriptomic writers on cancer types
using cBioPortal database, it was found that ALRYEF, CDKAL1, GTPBP3, METTL11B,
METTL18 and METTL23 had high levels of amplification frequency; FTSJ1 had a high level of
deep deletion frequency and METTL24 had high level of mutation frequency. ALYREF (m5C) is
a methytransferase reader enzyme that modifies position 48, 49 and 50 of tRNA (Yang et al., 2017,
Boccaletto et al., 2017). CDKAL1 (ms2t6A) is a methylthiotransferase writer enzyme that modifies
position 37 of tRNA (Wei et al., 2011). FTSJ1 (2’-O methyl ribose) is a methyltransferase writer
enzyme that modifies position 32 and 34 of tRNA (Dimitrova et al., 2019). METTL11B, a
methyltransferase-like 11B writer enzyme and METTLL18, a methyltransferase-like 18 writer
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enzyme, had almost same levels of amplification frequency in Breast Mixed Ductal and Lobular
Carcinoma, Breast Invasive Lobular Carcinoma and Breast Invasive Ductal Carcinoma among
many other cancer types. This raises a question on whether these two writers are related or function
with similar roles in the development of cancer cells. While the deep deletion frequency was low
in different cancer types for ELP3 (mcm5s2U), an acetyltransferase enzyme that modifies position
34 of tRNA (Bjork et al., 2019), the highest type of alteration seen in each cancer type was deep
deletion. Therefore, it can be assumed that ELP3 plays a big role in deep deletion for many
different types of cancers.
Two common cancers that had high alteration frequency for many human epitranscriptomic
writers were Bladder/ Urinary Tract cancer and Uterine Serous Carcinoma/ Uterine Papillary
Serous Carcinoma. Bladder cancer is a specific Urinary Tract cancer and is one of the most
common cancers in the world (Yaxley, 2016). Unlike most cancer types, the risk of having bladder
cancer is not associated with family history (Yaxley, 2016). Rather, the most probable etiology of
bladder cancer is found to be a mix between environmental and genetic factors (Yaxley, 2016).
The biggest known risk factors for developing bladder cancer is smoking cigarette and everyday
exposure for those working in “chemical and textile industries” (Yaxley, 2016). This disease is
seen less frequently in women than men (Yaxley, 2016). Meanwhile, Uterine Serous Carcinoma
(USC) is a rare variant (Type II) of endometrial cancer that includes less than 10% of endometrial
cancers (Zhang et al., 2020). Despite this, USC causes almost 80% of all endometrial cancer deaths
and is known to be a very aggressive variant (Zhang et al., 2020). It is most endemic in women
70 years and over in age (Zhang et al., 2020). Due to its poor prognosis, extremely aggressive
effects and lack of proper treatment compared to other endometrial cancer, there has been a rapid
upward trend in the number of deaths due to USC each year (Black et al., 2014; Zhang et al., 2020)

43

In general, it can be seen that human epitranscriptomic writers: ALRYEF, CDKAL1, FTSJ1,
GTPBP3, METTL11B, METTL18, METTL23 and METTL24 have high levels of alteration
frequencies for specific cancer types. Therefore, we can conclude that these writers could play an
important role for those specific cancer developments, and hence can be used as a potential cancer
treatment target, especially for cancers like USC where a typical cancer treatment such as
chemotherapy and radiotherapy is not a great option.
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